Literature DB >> 19134488

Palliative care for the patient with refractory chronic rhinosinusitis.

Elizabeth J Mahoney1, Ralph Metson.   

Abstract

Most otolaryngologists encounter patients with chronic rhinosinusitis who, despite conventional medical and surgical therapy, fail to show significant symptomatic improvement. Many paradigms have been proposed to explain the mechanisms responsible for refractory disease in these patients, including superantigen activation, biofilm formation, and eosinophil activation triggered by fungal elements. Although the precise underlying etiology of this clinical scenario remains unclear, the resultant pathophysiologic events share a final common pathway marked by inflammatory changes of the sinonasal mucosa. This article reviews the proposed hypotheses as to why some patients with chronic sinusitis fail conventional therapy and highlights treatment options useful in the palliative treatment of these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19134488     DOI: 10.1016/j.otc.2008.09.009

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  3 in total

1.  Topical antibiotic therapy of chronic rhinosinusitis.

Authors:  Richard H Comstock; Kent Lam; Suzette Mikula
Journal:  Curr Infect Dis Rep       Date:  2010-03       Impact factor: 3.725

2.  Histologic characteristics and mucin immunohistochemistry of cystic fibrosis sinus mucosa.

Authors:  Xiaofang Wu; Melissa M Amorn; Pawandeep K Aujla; Shannon Rice; Remy Mimms; Alan M Watson; Jennifer R Peters-Hall; Mary C Rose; Maria T Peña
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2011-04

3.  Effects of glucocorticoid on the expression and regulation of aquaporin 5 in the paranasal sinus of rats with chronic rhinosinusitis.

Authors:  Chen-Jie Yu; Xin-Yan Cui; Ling Lu; Jun Yang; Bin Chen; Cheng-Wen Zhu; Xia Gao
Journal:  Exp Ther Med       Date:  2017-03-09       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.